Ischemic Stroke
Conditions
Brief summary
This study aims to investigate the correlation of serum osteopontin level as a predictior and a prognostic factor in upper egyptian patients and correlation between Osteopontin Gene Polymorphisms and serum level of osteopontin in ischaemic stroke patients
Detailed description
The Global Burden of Disease estimated that one person in four aged 25 years will have a stroke in the rest of her/his life. Among them, ischemic stroke (IS) represents 80%. Stroke is accompanied by a neuroinflammatory response involving immune system. These long-term processes following IS are still far from being understood. So, despite the significant improvement in the diagnosis and treatment of IS, the disability and mortality rate of IS are still rising. An assessment of the prognostic risk of IS should be carried out as early as possible and corresponding interventions should be adopted clinically, in order to have a significant impact on the prognosis of patients with IS. Predicting the outcome in individual patients solely based on clinical and radiological parameters is challenging for clinicians. Measuring blood biomarkers associated with inflammation, endothelial function, matrix remodeling, and immune functions, may improve prediction performance . Osteopontin (OPN) is a matricellular protein participating in many physiological and pathologic processes including wound healing, bone turnover, tumor genesis, inflammation, and immune responses . It is well accepted that OPN is an important mediator in stroke pathophysiology. OPN expression is upregulated in microglia surrounding the infarcted area and in microglia and infiltrating macrophages in the infarct area. OPN and microglia seems to exhibit an intimate relationship in stroke with rather beneficial functions for the clinical outcome. However, the role of OPN in stroke-related diseases as atherosclerosis and diabetes should be further disentangled as in this early phase of disease OPN may ultimately culminate in cerebrovascular dysfunction. OPN may exert opposing effects and should be therefore addressed differently.
Interventions
GENETICGene polymorphism from blood samples
Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers. Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis. Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation
Sponsors
Assiut University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
* For acute ischemic stroke cases: ( Acute ischemic stroke will be defined as an episode of focal neurological deficits lasting for more than 24 hour with relevant lesion in brain computerized tomography (CT) or magnetic resonance (MR) image\>) 1- both sex 2- Age between 18 to 70 years old. 3-symptoms suggestive of acute ischemic stroke: presenting within 24 hours of onset of these symptoms * For old ischemic stroke: 1. both sex 2. Age between 18 to 70 years old. 3. Duration of3to 6 month of development of ischemic symptoms * For control cases: 1. both sex 2. Healthy people 3. Age: above 18 years old
Exclusion criteria
Patients with a previous history of stroke; Patients with hemorrhagic stroke. Patients with coronary heart disease, heart failure, chronic inflammation, intracranial infection/brain tumor and malignant tumor. Patients with liver, kidney and other important organ dysfunction. Patients with severe abnormal coagulation function
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure osteopontin level in ischaemic stroke patients and different gene polymorphisms related to the disease | Baseline | investigate the correlation of serum osteopontin level as a predictior and a prognostic factor in upper egyptian patients. Correlation between Osteopontin Gene Polymorphisms and serum level of osteopontin in ischaemic stroke patients |
Contacts
Primary ContactMadonna Nabil, Demonstrator
Backup ContactThoraya Eldeeb, Professor
Outcome results
None listed